10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
51 citations
,
August 2010 in “British journal of dermatology/British journal of dermatology, Supplement” Intralesional triamcinolone acetonide helps regrow eyebrows in patients with frontal fibrosing alopecia.
3 citations
,
June 1983 in “Archives of Dermatology” Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
4 citations
,
December 2020 Methotrexate may help stabilize frontal fibrosing alopecia.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery” June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
25 citations
,
December 2017 in “Facial Plastic Surgery” Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
16 citations
,
January 2007 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” The document concludes that there are no reliable treatments for frontal fibrosing alopecia, with only temporary benefits from current options.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
The patient improved with treatment for depilating folliculitis.
January 2025 in “Journal of Food Biochemistry” 2′‐Fucosyllactose reduces hair loss and promotes hair growth in mice.
9 citations
,
July 2019 in “Dermatologic therapy” Alitretinoin can effectively treat frontal fibrosing alopecia.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet”
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
July 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” Excessive sun protection might contribute to frontal fibrosing alopecia.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
1 citations
,
May 2024 in “Cureus” Combining oral isotretinoin and rifampicin effectively treats folliculitis decalvans.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
July 2025 in “Journal of the European Academy of Dermatology and Venereology” A new treatment plan helps manage folliculitis decalvans effectively.